BRPI0408238A - anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer - Google Patents

anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer

Info

Publication number
BRPI0408238A
BRPI0408238A BRPI0408238-9A BRPI0408238A BRPI0408238A BR PI0408238 A BRPI0408238 A BR PI0408238A BR PI0408238 A BRPI0408238 A BR PI0408238A BR PI0408238 A BRPI0408238 A BR PI0408238A
Authority
BR
Brazil
Prior art keywords
cancer
pharmaceutical composition
detecting
detecting cancer
antibody
Prior art date
Application number
BRPI0408238-9A
Other languages
English (en)
Inventor
Kimihisa Ichikawa
Shu Takahashi
Toshinori Agatsuma
Keisuke Fukuchi
Takehiro Hirai
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0408238A publication Critical patent/BRPI0408238A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTICORPO, MéTODO DE DETECTAR CáNCER,CONJUNTO PARA DETECçãO DE CáNCER, E, COMPOSIçãO FARMACêUTICA PARA TRATAR CáNCER". Método de detectar câncer com o uso de oncogene; um método de triar compostos capazes de exercer efeitos de tratamento e/ou prevenção de câncer e uma composição farmacêutica para o tratamento e/ou prevenção de câncer. Em particular, um método de detectar câncer em que a expressão de um gene de oculospanina humana é usado como um índice e uma composição farmacêutica que compreende um anticorpo capaz de reconhecer especificamente a oculospanina humana e capaz de apresentar atividade citotóxica às células de carcinoma.
BRPI0408238-9A 2003-03-10 2004-03-09 anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer BRPI0408238A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003063648 2003-03-10
PCT/JP2004/003048 WO2004081050A1 (ja) 2003-03-10 2004-03-09 癌特異的抗原を標的とした抗体

Publications (1)

Publication Number Publication Date
BRPI0408238A true BRPI0408238A (pt) 2006-03-01

Family

ID=32984436

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408238-9A BRPI0408238A (pt) 2003-03-10 2004-03-09 anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer

Country Status (19)

Country Link
US (4) US7855056B2 (pt)
EP (1) EP1602669B1 (pt)
JP (1) JP4462964B2 (pt)
KR (1) KR20050116374A (pt)
CN (2) CN102151334A (pt)
AT (1) ATE434044T1 (pt)
AU (1) AU2004220182B2 (pt)
BR (1) BRPI0408238A (pt)
CA (1) CA2518787A1 (pt)
DE (1) DE602004021567D1 (pt)
DK (1) DK1602669T3 (pt)
ES (1) ES2327408T3 (pt)
MX (1) MXPA05009715A (pt)
NO (1) NO20054631L (pt)
NZ (1) NZ542220A (pt)
RU (1) RU2345090C2 (pt)
TW (1) TW200508249A (pt)
WO (1) WO2004081050A1 (pt)
ZA (1) ZA200507298B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170368A1 (en) * 2003-07-02 2005-08-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20110194996A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Transport container for stabilized liquid samples
EP2613380B1 (en) 2010-11-05 2015-03-18 LG Chem, Ltd. Enhanced-stability rechargeable battery
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US20140224373A1 (en) * 2013-02-12 2014-08-14 MPS Enterprises, Inc. Lay-flat hose for oilfield hydraulic fracturing operations
WO2016055609A1 (en) * 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
KR102665199B1 (ko) * 2018-11-15 2024-05-14 삼성디스플레이 주식회사 레이저 장치 및 이를 이용한 기판 식각 방법
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5792456A (en) * 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
US5728821A (en) 1994-08-04 1998-03-17 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
KR20000070989A (ko) * 1997-02-12 2000-11-25 나가야마 오사무 임파구계 종양의 치료제
AU752031B2 (en) 1998-05-08 2002-09-05 Toyama Chemical Co. Ltd. Novel spiro compounds or salts thereof, agent for preventing and/or treating autoimmune diseases and AP-1 inhibitors containing the same
CN1399645A (zh) * 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020172986A1 (en) * 2000-08-21 2002-11-21 Leiby Kevin R. 23228, a novel human tetraspanin family member and uses thereof
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2459219A1 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20070042360A1 (en) 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7361342B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US20050170368A1 (en) 2003-07-02 2005-08-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Also Published As

Publication number Publication date
JP2004290187A (ja) 2004-10-21
ZA200507298B (en) 2006-06-28
CN102151334A (zh) 2011-08-17
TW200508249A (en) 2005-03-01
EP1602669A4 (en) 2006-08-09
US20070025996A1 (en) 2007-02-01
CA2518787A1 (en) 2004-09-23
AU2004220182B2 (en) 2007-12-06
NZ542220A (en) 2008-04-30
CN1784426A (zh) 2006-06-07
WO2004081050A1 (ja) 2004-09-23
JP4462964B2 (ja) 2010-05-12
NO20054631D0 (no) 2005-10-07
HK1078593A1 (en) 2006-03-17
US20060127405A1 (en) 2006-06-15
DE602004021567D1 (de) 2009-07-30
NO20054631L (no) 2005-12-09
ATE434044T1 (de) 2009-07-15
MXPA05009715A (es) 2005-10-18
EP1602669A1 (en) 2005-12-07
US7741447B2 (en) 2010-06-22
EP1602669B1 (en) 2009-06-17
US7855056B2 (en) 2010-12-21
AU2004220182A1 (en) 2004-09-23
US20080146785A1 (en) 2008-06-19
DK1602669T3 (da) 2009-09-14
US7361340B2 (en) 2008-04-22
RU2005128277A (ru) 2006-06-10
KR20050116374A (ko) 2005-12-12
US20070166312A1 (en) 2007-07-19
ES2327408T3 (es) 2009-10-29
RU2345090C2 (ru) 2009-01-27

Similar Documents

Publication Publication Date Title
WO2003080582A3 (de) Fredericamycin-derivate
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA201400111A1 (ru) Ингибиторы mek и способы их применения
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
ATE552000T1 (de) Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
DK1602669T3 (da) Antistof mod et tumor-specifikt antigen som target
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE602004027086D1 (de) Klassifizierung von kolonkrebs
ATE397924T1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
DE60227417D1 (de) Verwendung von emp9 zur prävention von proliferativen organerkrankungen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60310975D1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
SE0203536D0 (sv) Use of a known substance for the treament of cancer and bacterial and fungal infections
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.